Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Agios Pharmaceuticals, Inc. (AGIO : NSDQ)

• Company Description    Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on development of treatments for rare genetic metabolic disorders, a subset of orphan genetic metabolic diseases. Number of Employees: 540

• Price / Volume Information    Yesterday's Closing Price: $28.14 Daily Weekly Monthly 20 Day Moving Average: 962,257 shares Shares Outstanding: 59.47 (millions) Market Capitalization: $1,673.54 (millions) Beta: 0.58 52 Week High: $46.00 52 Week Low: $22.24 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 9.32% 3.98% 12 Week -6.14% -13.23% Year To Date 3.38% -2.76%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 88 SIDNEY STREET - CAMBRIDGE,MA 02139 USA ph: 617-649-8600 fax: - morgan.sanford@agios.com http://www.agios.com

• General Corporate Information    Officers Brian Goff - ChiefExecutiveOfficer Jacqualyn A. Fouse - Chair of the Board of Directors Cecilia Jones - Chief Financial Officer T.J. Washburn - Vice President; Controller Jay Backstrom - Director Peer Information Agios Pharmaceuticals, Inc. (CORR.) Agios Pharmaceuticals, Inc. (RSPI) Agios Pharmaceuticals, Inc. (CGXP) Agios Pharmaceuticals, Inc. (BGEN) Agios Pharmaceuticals, Inc. (GTBP) Agios Pharmaceuticals, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00847X104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 07/30/26 Share - Related Items Shares Outstanding: 59.47 Most Recent Split Date: (:1) Beta: 0.58 Market Capitalization: $1,673.54 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.67 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-6.17 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 32.70% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 07/30/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.51 Price/Cash Flow: - Price / Sales: 25.34 EPS Growth vs. Year Ago Period: -9.03% vs. Previous Quarter: 8.65% Sales Growth vs. Year Ago Period: 137.75% vs. Previous Quarter: 3.90% ROE 03/31/26 - -34.11 12/31/25 - -31.07 09/30/25 - -28.35 ROA 03/31/26 - -31.66 12/31/25 - -28.92 09/30/25 - -26.42 Current Ratio 03/31/26 - 14.19 12/31/25 - 11.46 09/30/25 - 13.82 Quick Ratio 03/31/26 - 13.59 12/31/25 - 11.06 09/30/25 - 13.39 Operating Margin 03/31/26 - -639.84 12/31/25 - -764.01 09/30/25 - -895.86 Net Margin 03/31/26 - -639.84 12/31/25 - -764.01 09/30/25 - -895.86 Pre-Tax Margin 03/31/26 - -641.38 12/31/25 - -765.89 09/30/25 - -915.68 Book Value 03/31/26 - 18.65 12/31/25 - 20.46 09/30/25 - 22.02 Inventory Turnover 03/31/26 - 0.20 12/31/25 - 0.20 09/30/25 - 0.19 Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©